Amida Care’s Doug Wirth says they should work with state-level officials to make sure services are covered after Biden administration’s guidance that coverage is mandatory.
Health plans leaders — especially those in charge of Medicaid managed care plans — are in a position to take a leadership role in making sure that services related to pre-exposure prophylaxis (PrEP) are covered after the Biden administration issued a guidance about the coverage last month, according to a leader of a community health plan that specializes in covering people with HIV/AIDS and other chronic conditions.
“Health plan leaders can be the thought leader working with state Medicaid directors on how to implement this in a way that plans are adequately funded and have the right the tools,” Doug Wirth, president and CEO of Amida Care in New York City, said in recent interview with Managed Healthcare Executive®.
Amida Care is a nonprofit community health plan that covers about 8,000 members in New York City, including people living with HIV/AIDS. people who are experiencing homelessness, regardless of HIV status; and people of transgender experience regardless of HIV status.
With PrEP, people at risk of contracting HIV take antiviral medication on a preventive basis to fend off the infection if they are exposed. The administration issued the guidance on July 19 to clarify that insurers must cover supporting services for people on PrEP, not just the medication itself. Those supporting services include HIV testing, hepatitis B and C testing, monitoring for any kidney damage that may result from taking the PrEP medications and adherence counseling.
“Previously, it was unclear whether PrEP-related services, beyond the medication, like provider visits, HIV tests, hepatitis and STI screening, were actually covered,” said Wirth. As a result, patients would face prior authorization delays, outright denial of coverage or cost sharing that made PrEP prohibitively expensive. Wirth described the administration’s guidance as a “game changer.”
Wirth said, though, that insurance commissioners at the state level and Medicaid directors “will need to take steps to ensure compliance and admonish insurers that ultimately break the law.”
The Medicaid programs in New York, California and Colorado are the leaders in PrEP utilization and Wirth said plans elsewhere ought to contact those state for data about access and utilization of PrEP.
FDA Accepts NDA for Gilead's New HIV Prevention Shot
February 18th 2025Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.
Read More
HIV + Hepatitis Institute Welcomes RFK, Talks Importance of Ending the HIV Epidemic
February 13th 2025The group released a statement today expressing that they are eager to work with Robert F. Kennedy Jr. to eradicate HIV when steps into his role as the Secretary of Health and Human Services.
Read More
Trump Administration Throws U.S. AIDS Support into Turmoil
February 6th 2025PEPFAR, the main U.S.-funded global AIDS program was given a waiver from the foreign aid freeze, but there is still uncertainty and interruptions, partly because many PEPFAR programs are implemented through USAID, which has been largely shutdown by the news administration.
Read More